ALZFORUM | NETWORKING FOR A CURE
WEB4 days ago · On September 10, Francisco Lopera died of cancer in Medellin, Colombia. He was widely beloved. Lopera helped pioneer prevention trials of disease-modifying drugs after years spent assembling information on the world’s largest known kindred of autosomal-dominant Alzheimer’s disease caused by …
Donanemab | ALZFORUM
WEBFeb 14, 2019 · Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813, Kisunla Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologic drug …
Aduhelm - ALZFORUM
WEBJan 3, 2016 · Overview. Name: Aduhelm Synonyms: Aducanumab, BIIB037 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: Biogen, Neurimmune Background. BIIB037 is a high-affinity, fully human IgG1 monoclonal antibody against a conformational epitope found on Aβ. It was originally derived by the biotech ...
Leqembi - ALZFORUM
WEBOverview. Name: Leqembi Synonyms: Lecanemab-irmb, BAN2401, mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: BioArctic AB, Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble ...
Trontinemab - ALZFORUM
WEBMay 9, 2024 · Overview. Name: Trontinemab Synonyms: RO7126209, RG6102 , Brain shuttle gantenerumab Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 1/2) Company: Hoffmann-La Roche Background. RO7126209 is a new version of the anti-amyloid monoclonal antibody gantenerumab, engineered to more easily cross the blood ...
Lecanemab Follows Aduhelm’s Path to Accelerated Approval
WEBOct 20, 2021 · The Food and Drug Administration's approval of aducanumab based on plaque removal rather than clinical benefit has thrown open the gates for other anti-amyloid therapeutic antibodies to follow the same route to market. Eisai/Biogen are already on that path with lecanemab, having applied to the FDA for a marketing license on September 27.
5xFAD (B6SJL) - ALZFORUM
WEBJan 18, 2015 · 5xFAD mice express human APP and PSEN1 transgenes with a total of five AD-linked mutations: the Swedish (K670N/M671L), Florida (I716V), and London (V717I) mutations in APP, and the M146L and L286V mutations in PSEN1. Three lines were generated originally: Tg6799, Tg7031, and Tg7092. The Tg6799 line, which expresses the highest levels of mutant ...
BIIB080 | ALZFORUM
WEBAt 54 sites across North America, Japan, Australia, and Europe, participants will receive high- or low-dose BIIB080 every 24 weeks, high dose every 12 weeks, or placebo, for 72 weeks. The primary outcome is the dose response in change of CDR-SB from baseline after 76 weeks. Secondary measures include ADCS-ADL-MCI, ADAS-Cog 13, MMSE, iADRS ...
Diabetes in Mid-Life Drives Up Dementia Risk | ALZFORUM
WEBApr 29, 2021 · In the April 27 JAMA, researchers led by Archana Singh-Manoux, INSERM, Paris, reported that the earlier diabetes sets in, the likelier—and the sooner—dementia may follow suit. Getting Type 2 diabetes before age 60 doubles dementia risk, and for every five years a person lives with diabetes, his or her dementia risk increases by 24 percent.
Semaglutide - ALZFORUM
WEBSemaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes. Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is is a daily pill. Rybelsus TM was approved by the U.S. FDA in September 2019 as the first GLP-1 analog that does not need to be injected.